OncologyOnline.net

Oncology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Search results for "Cabometyx"

Results from phase 2 CABOSUN trial of Cabozantinib ( Cabometyx ) versus Sunitinib ( Sutent ) in previously untreated advanced renal cell carcinoma were presented at the European Society for Medical On ...


Cabozantinib ( Cabometyx ) may enhance response to immune checkpoint inhibitors ( ICIs ) by promoting an immune-permissive microenvironment and has shown encouraging activity in combination with ICIs ...


While studies have demonstrated survival benefits of first-line regimens including immuno-oncology agents ( IO ) in advanced renal cell carcinoma ( aRCC ), optimal treatment following onco-immunothera ...


First-line immunotherapy with / without chemotherapy is standard of care for patients with advanced non-small-cell lung cancer ( NSCLC ); however, there is a need for effective treatment options after ...


Previous treatment with immune checkpoint inhibitor ( ICI ) is more common in clinical practice since recent FDA-approval of 5 ICIs in second-line and 2 in first-line for metastatic urothelial carcino ...


Non-clear cell renal cell carcinoma ( nccRCC ) encompasses a heterogenous group of histologies comprising approximately 25% of all renal cell carcinoma ( RCC ) diagnoses with worse outcomes than clear ...